Morgan Stanley
ENTA icon

Morgan Stanley’s Enanta Pharmaceuticals ENTA Stock Holding History

Morgan Stanley’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.91M Sell
309,511
-30,407
-9% -$408K ﹤0.01% 4314
2025
Q4 		$5.36M Buy
339,918
+57,287
+20% +$728K ﹤0.01% 4118
2025
Q3 		$3.38M Sell
282,631
-3,895
-1% -$31.1K ﹤0.01% 4443
2025
Q2 		$2.17M Sell
286,526
-198,965
-41% -$1.2M ﹤0.01% 4647
2025
Q1 		$2.68M Sell
485,491
-736,104
-60% -$4.55M ﹤0.01% 4421
2024
Q4 		$7.02M Buy
1,221,595
+118,743
+11% +$1.14M ﹤0.01% 3698
2024
Q3 		$11.4M Sell
1,102,852
-353,707
-24% -$4.62M ﹤0.01% 3326
2024
Q2 		$18.9M Sell
1,456,559
-588,586
-29% -$7.95M ﹤0.01% 2726
2024
Q1 		$35.7M Sell
2,045,145
-300,971
-13% -$3.98M ﹤0.01% 2080
2023
Q4 		$22.1M Buy
2,346,116
+1,781,550
+316% +$16.6M ﹤0.01% 3238
2023
Q3 		$6.31M Buy
564,566
+257,264
+84% +$4.14M ﹤0.01% 3547
2023
Q2 		$6.58M Buy
307,302
+175,354
+133% +$5.17M ﹤0.01% 3554
2023
Q1 		$5.34M Sell
131,948
-6,577
-5% -$314K ﹤0.01% 3732
2022
Q4 		$6.44M Sell
138,525
-43,149
-24% -$1.97M ﹤0.01% 3508
2022
Q3 		$9.42M Sell
181,674
-63,200
-26% -$3.69M ﹤0.01% 3043
2022
Q2 		$11.6M Buy
244,874
+78,326
+47% +$4.25M ﹤0.01% 2913
2022
Q1 		$11.9M Buy
166,548
+40,479
+32% +$2.63M ﹤0.01% 2706
2021
Q4 		$9.43M Sell
126,069
-36,163
-22% -$2.84M ﹤0.01% 3009
2021
Q3 		$9.22M Sell
162,232
-13,975
-8% -$691K ﹤0.01% 2993
2021
Q2 		$7.76M Buy
176,207
+30,356
+21% +$1.49M ﹤0.01% 3286
2021
Q1 		$7.19M Sell
145,851
-12,305
-8% -$614K ﹤0.01% 3020
2020
Q4 		$6.66M Buy
158,156
+67,901
+75% +$2.99M ﹤0.01% 2950
2020
Q3 		$4.13M Buy
90,255
+27,983
+45% +$1.36M ﹤0.01% 2897
2020
Q2 		$3.13M Sell
62,272
-5,896
-9% -$305K ﹤0.01% 3143
2020
Q1 		$3.51M Sell
68,168
-167,990
-71% -$8.95M ﹤0.01% 2803
2019
Q4 		$14.6M Buy
236,158
+69,848
+42% +$4.33M ﹤0.01% 1974
2019
Q3 		$9.99M Buy
166,310
+57,346
+53% +$4.26M ﹤0.01% 2128
2019
Q2 		$9.19M Buy
108,964
+31,335
+40% +$2.82M ﹤0.01% 2257
2019
Q1 		$7.42M Sell
77,629
-114,507
-60% -$10.3M ﹤0.01% 2335
2018
Q4 		$13.6M Buy
192,136
+152,246
+382% +$11.7M ﹤0.01% 1803
2018
Q3 		$3.41M Sell
39,890
-11,877
-23% -$1.19M ﹤0.01% 3567
2018
Q2 		$6M Sell
51,767
-5,808
-10% -$580K ﹤0.01% 2944
2018
Q1 		$4.66M Buy
57,575
+10,806
+23% +$832K ﹤0.01% 3101
2017
Q4 		$2.75M Buy
46,769
+12,774
+38% +$640K ﹤0.01% 3738
2017
Q3 		$1.59M Buy
33,995
+3,155
+10% +$127K ﹤0.01% 4082
2017
Q2 		$1.11M Sell
30,840
-7,586
-20% -$243K ﹤0.01% 4297
2017
Q1 		$1.18M Sell
38,426
-11,834
-24% -$369K ﹤0.01% 4253
2016
Q4 		$1.68M Buy
50,260
+45,008
+857% +$1.29M ﹤0.01% 4072
2016
Q3 		$140K Sell
5,252
-3,674
-41% -$85.3K ﹤0.01% 5165
2016
Q2 		$196K Buy
8,926
+2,044
+30% +$53.5K ﹤0.01% 4947
2016
Q1 		$202K Sell
6,882
-3,872
-36% -$108K ﹤0.01% 4972
2015
Q4 		$356K Buy
10,754
+6,655
+162% +$217K ﹤0.01% 4762
2015
Q3 		$148K Sell
4,099
-917
-18% -$39.4K ﹤0.01% 5234
2015
Q2 		$226K Sell
5,016
-3,679
-42% -$143K ﹤0.01% 5175
2015
Q1 		$266K Sell
8,695
-2,780
-24% -$108K ﹤0.01% 5049
2014
Q4 		$584K Buy
11,475
+6,957
+154% +$311K ﹤0.01% 4559
2014
Q3 		$179K Sell
4,518
-311
-6% -$12.4K ﹤0.01% 5201
2014
Q2 		$208K Sell
4,829
-390
-7% -$14.9K ﹤0.01% 5132
2014
Q1 		$208K Sell
5,219
-1,006
-16% -$36.5K ﹤0.01% 5098
2013
Q4 		$170K Buy
+6,225
New +$151K ﹤0.01% 5099
2013
Q3 		– Sell
-43,678
Closed -$773K – 5335
2013
Q2 		$773K Buy
+43,678
New +$852K ﹤0.01% 3928

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley's ENTA Position: Q1 2026 in Review

Morgan Stanley reduced its Enanta Pharmaceuticals (ENTA) stake by 8.9% in Q1 2026, selling an estimated $408K and leaving 309,511 shares worth $3.91M. The position accounts for ﹤0.01% of the portfolio, ranked #4314.

Morgan Stanley first reported a position in ENTA in Q2 2013 and has held it in 51 quarters since. The position peaked at $35.7M in Q1 2024. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Morgan Stanley held 309,511 shares of Enanta Pharmaceuticals worth $3.91M as of Q1 2026.
  • Morgan Stanley sold 30,407 Enanta Pharmaceuticals shares in Q1 2026, an estimated $408K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4314 holding.
  • Morgan Stanley first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Morgan Stanley's Enanta Pharmaceuticals position peaked at $35.7M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.